Five-Year Trajectory of Mild Cognitive Impairment: Insights from a Primary Care Memory Clinic

Linda Lee1, Aaron Jones2, Tejal Patel3

  • 1Department of Family Medicine, McMaster University, Hamilton, ON, Canada and Centre for Family Medicine Family Health Team, Kitchener, ON, Canada.

Abstract

Insights

The 5-year risk of Mild Cognitive Impairment (MCI) progressing to dementia is estimated at 48.8%, with higher Montreal Cognitive Assessment (MoCA) scores indicating a lower risk. Primary care memory clinics aid early detection.

Area of Science:

  • Neurology
  • Gerontology
  • Primary Care Medicine

Background:

  • The progression of Mild Cognitive Impairment (MCI) to dementia in primary care settings remains poorly understood.
  • Early identification and intervention are crucial for managing cognitive decline.

Purpose of the Study:

  • To investigate the 5-year trajectory of patients diagnosed with MCI.
  • To assess dementia risk factors including age, sex, and Montreal Cognitive Assessment (MoCA) scores.
  • To determine the annual conversion rate from MCI to dementia in a memory clinic setting.

Main Methods:

  • A longitudinal cohort study involving a retrospective chart review of 751 patients.
  • Utilized Kaplan-Meier method for conversion rate estimation.
  • Employed Cox regression to analyze time to dementia and MoCA score association.

Main Results:

  • The estimated 5-year conversion rate from MCI to dementia was 48.8%, with an average annual rate of 9.8%.
  • A one-point increase in baseline MoCA score was linked to a 10% reduced risk of dementia conversion.
  • Observed 5-year conversion rate was 28.0% with limited follow-up data.

Conclusions:

  • Highlights the characteristics of patients seen in Multispecialty Interprofessional Team (MINT) memory clinics.
  • Provides insights into the cognitive trajectory of individuals with MCI.
  • Underscores the significance of primary care-based memory clinics for early detection and intervention.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
523
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
780
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Role of Cerebellum and Prefrontal Cortex in Memory01:14

Role of Cerebellum and Prefrontal Cortex in Memory

The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
1.1K
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
456